Inherited retinal diseases are a leading cause of blindness in working age adults in many countries. X-linked retinitis pigmentosa (RP) accounts for a significant proportion, with the majority associated with pathogenic variants in the RPGR gene. Although currently untreatable, 2 phase III gene therapy trials are ongoing (NCT04850118 and NCT04671433). Patients experience debilitating restriction of the visual field, but a key additional milestone is the subsequent loss of central vision. We collected visual acuity (VA) data from the large patient cohort with molecularly proven RPGR-associated RP in our center, aiming to quantify average VA for each decade, specifically identifying the decade in which this declined to 1.0 logMAR of the minimum angle of resolution (logMAR) or worse. We also investigated correlation between right and left eye acuities for all visits.

The analysis was restricted to male patients and to those with the more common rod-cone dystrophy/RP phenotype. The diagnosis of rod-cone dystrophy was made on the basis of visual symptoms (typically night vision difficulties followed by peripheral visual field loss), features on clinical examination and retinal imaging (including bone spicule pigmentation or predominantly peripheral retinal atrophy), and, if available, electrodiagnostic testing. Those with the later-presenting macular dystrophy, cone dystrophy, or cone-rod dystrophy phenotypes were not included in the main study. Best-later-presenting macular dystrophy, cone dystrophy, or cone-rod dystrophy phenotypes were not included in the main study. Best-recorded VA in each eye was converted to logMAR units (with qualitative acuities treated using previously published conversions, described in the legend to Fig 1). For quantification of average acuity per decade, if patients had multiple visits within the same decade, only 1 of these visits (the first) was included, so that no patient was included more than once in each decade. The study had relevant institutional review board approval (Moorfields Eye Hospital and the Northwest London Research Ethics Committee); the study adhered to the Declaration of Helsinki and patients gave informed consent.

Data were analyzed from 771 patient visits (139 patients). Across all visits, mean (standard deviation [SD]) patient age was 32 (15) years and the median age was 33 years. Mean (SD) logMAR VA was 0.82 (0.81) and 0.86 (0.82) for right and left eyes, respectively; medians were 0.5 and 0.5, respectively. Figure 1 shows average (mean and median) VAs for right and left eyes by decade. Numeric values are given in Table S1 (available at www.ophthalmologyscience.org). Distributions of VAs in each decade are shown in the plots in Figure S2 (available at www.ophthalmologyscience.org). As well as shifting toward worse acuities in the older decades, the distributions become more dispersed, and some eyes (a minority) had VAs worse than 1.0 logMAR in the third and fourth decades. Correlations of acuity with age were 0.66 and 0.67 for right and left eyes, respectively (P < 0.001).

Figure S3 (available at www.ophthalmologyscience.org) shows right and left eye acuities across all visits. The coefficient of interocular correlation was 0.88 (P < 0.001). The high interocular correlation was expected, consistent with largely symmetric disease in men. However, significant interocular differences were also seen, particularly for worse VAs: the mean (SD) absolute interocular difference was 0.12 (0.22) for patients with acuities better than 1.0 logMAR (averaged across both eyes); the mean (SD) difference was 0.43 (0.54) for those with 1.0 logMAR or worse. This is relevant when fellow eyes serve as controls in therapy trials.

When quantifying VA by decade in our cohort of > 130 patients (larger than previously published cohorts), we found that both mean and median VA reached 1.0 logMAR or worse in the fifth decade for both right and left eyes, and for the better-seeing eye; thus, the majority of patients had vision of this level or worse from this decade onward. The mean age of patients whose VA was 1.0 logMAR or worse in their better-seeing eye was 44 years (median, 45 years). Our results are largely consistent with data from previous RPGR-associated rod-cone dystrophy cohorts, with 1 study reporting the median age to legal blindness at the age of 45 years (n = 113), and another reporting a 20% probability of reaching the threshold of legal blindness at the age of 40 years (n = 52).

There were 16 additional patients in our cohort with RPGR-associated cone or cone-rod dystrophy (excluded from the above analysis). Data were available from 102 patient visits: across all visits, mean (SD) patient age was 45 (10) years; median age was 47.5 years. Mean (SD) logMAR VA was 1.1 (0.18) and 1.1 (0.44) for right and left eyes, respectively; medians were 1.0 and 1.0, respectively. These findings are consistent with patients with this phenotype presenting at an older age than those with rod-cone dystrophy (the median age of patients with rod-cone dystrophy was 33 years). In contrast to the rod-cone phenotype, patients with the cone or cone-rod dystrophy usually present with VA reduction. Given the difference in presentation and disease natural history, data from these patients were not included in our main analysis. Also, patients with this phenotype are not currently being recruited to the RPGR gene therapy trials.

Limitations of this study include its retrospective nature and that visual field data were not available. Most patients with the RP phenotype have extensive visual field loss, resulting in severe sight impairment, before the fifth decade. However, the timing of loss of central vision is an important additional feature of the natural history which has a marked stepwise impact on functional vision, and our finding that there is greater interocular asymmetry at worse levels of acuity is important for informing clinical trial design. These findings will inform counseling of patients and evaluation of net benefit of new treatments, including helping define the potential window for therapeutic Intervention.

Samantha R. de Silva, DPhil, FRCOphth1, 2
Hwei Wuen Chan, MD, FRCOphth1, 2
Aditi Agarwal, MRCPath, FICO1, 2
Andrew R. Webster, MD, FRCOphth1, 2
Michel Michaelides, MD, FRCOphth1, 2
Omar A. Mahroo, PhD, FRCOphth1, 2, 3, 4

1UCL Institute of Ophthalmology, University College London, London, United Kingdom; 2Genetics Service, Moorfields Eye Hospital, London,
The other authors have no proprietary or commercial interest in any materials discussed in this article.

Supported by the Wellcome Trust (206619_Z_17_Z) and the NIHR Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology. The sponsor or funding organization had no role in the design or conduct of this research.

HUMAN SUBJECTS: Human subjects were included in this study. The study had relevant institution review board approval (Moorfields Eye Hospital and the Northwest London Research Ethics Committee) and adhered to the tenets of the Declaration of Helsinki. All patients provided informed consent.

No animal subjects were included in this study.

Author Contributions:
Conception and design: Mahroo
Data collection: De Silva, Chan, Agarwal, Webster, Michaelides, Mahroo
Analysis and interpretation: De Silva, Chan, Agarwal, Webster, Michaelides, Mahroo
Obtained funding: Webster, Michaelides, Mahroo
Overall responsibility: De Silva, Webster, Michaelides, Mahroo

Abbreviations and Acronyms:
logMAR = logarithm of the minimum angle of resolution; RP = retinitis pigmentosa; SD = standard deviation; VA = visual acuity.

Keywords:
Inherited retinal degeneration, Retinitis pigmentosa, RPGR, Visual acuity.

Correspondence:
Professor Omar Mahroo, 11-43 Bath Street, London, EC1V 9EL, UK.
E-mail: o.mahroo@ucl.ac.uk.

References